Vibrio cholerae strain CVD103Hg.sup.r, method of making same, and vaccines derived therefrom

• US 5,628,994 A
• Filed: 12/01/1994
• Issued: 05/13/1997
• Est. Priority Date: 03/04/1983
• Status: Expired due to Term

• Current Assignee: University of Maryland
• Original Assignee: University of Maryland
• Inventors: Levine, Myron M., Kaper, James B.
• Primary Examiner(s): JACOBSON, DIAN COOK
• Application Number:
  US08/352,773
• Time in Patent Office: 894 Days
• Field of Search: 435/172.3, 435/252.1, 435/252.3, 435/901, 435/172.1, 424/92.3, 424/93.4
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2039/522 avirulent or attenuated
• CPC Class Codes: A61K 39/107 Vibrio
• CPC Class Codes: C07K 14/28 from Vibrionaceae (F)
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12N 15/01 Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
• CPC Class Codes: C12R 2001/63 Vibrio
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10S 435/909 Vibrio

Abstract

Method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain, CVD103Hg (ATTC No. 55,456), having a deletion in the tox gene, as defined by Acc I, Xba I, Cla I and/or restriction endonuclease sites, and carrying a mercury resistance gene. The invention also includes vaccines for protecting against the symptoms of cholera as well as methods for achieving this protection.

Claims

1. A vaccine for protecting against cholera comprising Vibrio cholerae having the identifying characteristics of Vibrio cholerae CVD103Hg^r (ATCC No. 55,456).

2. The vaccine according to claim 1 wherein said Vibrio cholerae is Vibrio cholerae CVD103Hg^r (ATCC No. 55,456).

3. The vaccine according to claim 2, wherein the number of organisms of said Vibrio cholerae CVD103Hg^r (ATCC No. 55,456) is about 10⁶.

4. The vaccine according to claim 2, wherein said Vibrio cholerae CVD103Hg^r (ATCC No. 55,456) is combined with at least one other strain of Vibrio cholerae.

5. The vaccine according to claim 2, wherein said Vibrio cholerae CVD103Hg^r (ATCC No. 55,456) is combined with a cholera toxoid.

6. The vaccine according to claim 2, wherein said vaccine is a live vaccine.

7. The vaccine according to claim 2, wherein said vaccine is a combination vaccine.

8. The vaccine according to claim 2, wherein said vaccine is effective in humans.

9. The vaccine for protecting against cholera according to claim 1, wherein the number of organisms of said Vibrio cholerae is about 10⁶.

10. The vaccine for protecting against cholera according to claim 1, wherein said Vibrio cholerae is combined with at least one other strain of Vibrio cholerae.

11. The vaccine for protecting against cholera according to claim 1, wherein said Vibrio cholerae is combined with a cholera toxoid.

12. The vaccine for protecting against cholera according to claim 1, wherein said vaccine is a live vaccine.

13. The vaccine for protecting against cholera according to claim 1, wherein said vaccine is a combination vaccine.

14. The vaccine for protecting against cholera according to claim 1, wherein said vaccine is effective in humans.

15. A pharmaceutical composition comprising:

Vibrio cholerae having the identifying characteristics of Vibrio cholerae CVD103Hg^r (ATCC No. 55,456) and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15, wherein said pharmaceutically acceptable carrier comprises sterile saline buffered from about pH 7.1 to about pH 7.3.

17. The pharmaceutical composition according to claim 15, wherein said Vibrio cholerae is combined with at least one other strain of Vibrio cholerae.

18. The pharmaceutical composition according to claim 15, wherein said Vibrio cholerae is combined with a cholera toxoid.

19. The pharmaceutical composition according to claim 15, wherein the number of organisms of said Vibrio cholera is about 10⁶.

20. The pharmaceutical composition according to claim 15 comprising Vibrio cholerae CVD103Hg^r (ATCC No. 55,456).

21. A method of protecting humans against cholera comprising:

obtaining a Vibrio cholerae culture comprising a Vibrio cholerae having substantially all of the identifying characteristics of Vibrio cholerae CVD103Hg^r (ATCC No. 55,456); and

administering an effective amount of said culture to a human.

22. The method for protecting humans against cholera according to claim 21, wherein said culture is administered orally.

23. The method for protecting humans against cholera according to claim 21, wherein said effective amount is in a single dose.

24. The method for protecting humans against cholera according to claim 21, wherein said CVD103Hg^r (ATCC No. 55,456) is administered in an amount effective against Vibrio cholerae classical biotypes selected from the group consisting of Inaba and Ogawa serotypes.

25. The method for protecting humans against cholera according to claim 24, wherein said CVD103Hg^r (ATCC No. 55,456) is administered in an amount effective against Vibrio cholerae selected from the group consisting of E1 Tor Inaba and E1 Tor Ogawa.

26. The method for protecting humans against cholera according to claim 25 wherein said E1 Tor Inaba is strain N16961, and said E1 Tor Ogawa is strain E7946.

27. The method for protecting humans against cholera according to claim 24 wherein said classical Inaba is strain 569B.

28. The method of claim 21, wherein said Vibrio cholerae culture is Vibrio cholerae CVD103Hg^r (ATCC No. 55,456).